LAUSR

OBJECTIVE To provide an overview of chimeric antigen receptor (CAR) T cell therapy for pediatric patients with relapsed or refractory malignancy and the associated toxicities. DATA SOURCES Research articles, reviews, clinical trial information. CONCLUSION The key to the successful application of CAR T cell immunotherapy is (1) identifying patients with malignancies that are eligible for immunotherapy, (2) coordinating T-cell collection, (3) safe infusion of CAR T cells, and (4) managing/preventing toxicities following infusion. IMPLICATIONS FOR NURSING PRACTICE As the use of targeted therapy with tumor-specific T cells becomes more prevalent, it is essential that the nursing staff stay abreast of these current therapies.